What are the adverse effects associated with lisinopril?

Lisinopril Side Effects

Lisinopril is generally well tolerated, but clinicians must monitor for common adverse effects including cough (occurs 2.5% more than placebo), dizziness (3.5% more than placebo), headache (3.8% more than placebo), and hypotension, while remaining vigilant for serious but rare complications such as angioedema (<1% incidence, higher in Black patients), hyperkalemia (2.2-4.8%), and acute kidney injury. 1

Common Adverse Effects (Occurring ≥2% More Than Placebo)

Cardiovascular and Neurological

• Dizziness/lightheadedness: Occurs in 3.5% more patients than placebo in hypertension trials 1
• Hypotension: Particularly problematic in heart failure patients (3.8% more than placebo) and post-MI patients (5.3% higher incidence) 1
• Headache: Affects 3.8% more patients than placebo 1
• Fatigue and asthenia: Common complaints reported in clinical practice 1

Respiratory

• Persistent dry cough: The most characteristic ACE inhibitor side effect, occurring 2.5% more frequently than placebo 1. This is a class effect related to bradykinin accumulation 2, 3. The cough typically resolves after drug withdrawal and recurs with rechallenge of any ACE inhibitor 2, 3

Gastrointestinal

• Diarrhea, nausea, constipation, flatulence, and dry mouth are reported in ≥1% of patients 1
• Pancreatitis has been reported but is uncommon 1

Serious Adverse Effects Requiring Immediate Attention

Angioedema (Life-Threatening)

• Occurs in <1% of patients overall but is more frequent in Black patients 2, 3
• Represents an absolute contraindication to all future ACE inhibitor use 2, 3
• Can be life-threatening and justifies permanent avoidance of all ACE inhibitors 2, 3
• When switching to an ARB after ACE inhibitor-induced angioedema, wait at least 6 weeks and use extreme caution, as angioedema has been reported with ARBs in patients with prior ACE inhibitor angioedema 4, 2, 3

Renal Complications

• Acute kidney injury and worsening renal function: Observed in approximately 2% of hypertensive patients, with higher rates (11.6%) in heart failure patients on concomitant diuretics 1
• Increases in blood urea nitrogen and serum creatinine are typically reversible upon discontinuation 1
• Particularly common in patients with renal artery stenosis or those receiving concomitant diuretics 1
• In post-MI patients, renal dysfunction (defined as creatinine >3 mg/dL or doubling of baseline) occurred in 2.4% vs 1.1% with placebo 1

Electrolyte Disturbances

• Hyperkalemia (serum potassium >5.7 mEq/L): Occurs in 2.2% of hypertensive patients and 4.8% of heart failure patients 1
• Risk is substantially increased when combined with:
  • Potassium-sparing diuretics
  • Potassium supplements
  • Aldosterone antagonists
  • Chronic kidney disease 5, 4, 6

Hematologic Effects

• Rare cases of bone marrow depression, hemolytic anemia, leukopenia/neutropenia, and thrombocytopenia have been reported 1
• Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.4 g% and 1 vol%, respectively) 1

Less Common But Clinically Significant Adverse Effects

Dermatologic

• Urticaria, alopecia, photosensitivity, erythema, flushing, diaphoresis 1
• Severe reactions: Toxic epidermal necrolysis, Stevens-Johnson syndrome, cutaneous pseudolymphoma 1
• Alopecia specifically associated with lisinopril has been documented in case reports, with resolution occurring within 4 weeks of discontinuation 7

Metabolic and Endocrine

• Diabetes mellitus and inappropriate antidiuretic hormone secretion 1
• Gout 1

Sensory

• Visual disturbances: Visual loss, diplopia, blurred vision, photophobia 1
• Auditory: Tinnitus 1
• Taste and smell disturbances (notably less common than with captopril) 8, 9

Genitourinary

• Impotence 1

Autoimmune-Like Syndrome

• A symptom complex may occur including: positive ANA, elevated ESR, arthralgia/arthritis, myalgia, fever, vasculitis, eosinophilia, leukocytosis, paresthesia, and vertigo 1

Special Population Considerations

Pregnancy (Category D)

• Absolutely contraindicated in second and third trimesters 1
• Causes fetal renal dysfunction, oligohydramnios, fetal lung hypoplasia, skeletal deformations, skull hypoplasia, anuria, hypotension, renal failure, and death 1
• Discontinue immediately when pregnancy is detected 1

Pediatric Patients

• Safety profile in children aged 6-16 years is similar to adults 10
• Common adverse effects in pediatric hypertension: cough, headache, dizziness, asthenia 10
• Severe adverse effects: hyperkalemia, acute kidney injury, angioedema, fetal toxicity (if used in adolescent pregnancy) 10

Elderly Patients

• No dosage adjustment necessary, but greater sensitivity cannot be ruled out 1
• In the GISSI-3 trial, 4.8% of patients ≥75 years discontinued due to renal dysfunction vs 1.3% of younger patients 1
• Elderly patients with severe heart failure are at greater risk for adverse events 11

Race-Specific Considerations

• Black patients have higher risk of angioedema 2, 3, 1
• ACE inhibitors have less blood pressure-lowering effect in Black patients compared to non-Black patients 1

Discontinuation Rates and Long-Term Tolerability

• In hypertension trials: 5.7% discontinued due to adverse reactions 1
• In heart failure trials: 8.1% discontinued after 12 weeks (vs 7.7% with placebo); 11% discontinued over up to 4 years 1
• Long-term safety data (up to 43 months) confirms good tolerability 8
• The ATLAS trial showed no difference in discontinuation rates between high-dose (32.5-35 mg) and low-dose (2.5-5 mg) lisinopril (17-18% in both groups) 12

Critical Management Pearls

Cough Management

• Encourage continuation if cough is not severe, given long-term mortality benefits 2, 3
• Only discontinue if cough is persistent and troublesome 2, 3
• Consider switching to an ARB if cough is intolerable, as ARBs do not cause cough 5, 4

Hypotension Management

• First-dose hypotension is uncommon (1.3% in hypertension, 4.8% in heart failure) 8
• Consider starting in the evening when supine to minimize blood pressure effects (though no heart failure data support this) 5
• Review and potentially reduce diuretic doses before initiating lisinopril 5

Renal Function Monitoring

• Check serum creatinine and potassium at baseline, 5-7 days after initiation, after each dose increase, at 1,3, and 6 months, then every 6 months 5, 4
• Discontinue if renal function deteriorates substantially 5
• Avoid NSAIDs and COX-2 inhibitors, which increase risk of renal dysfunction 5